EU/3/05/269

Table of contents

About

On 10 March 2005, orphan designation (EU/3/05/269) was granted by the European Commission to Janssen-Cilag International N.V., Belgium, for tipifarnib for the treatment of acute myeloid leukaemia.

The sponsorship was transferred to TMC Pharma Services Ltd, United Kingdom, in June 2015 and subsequently to TMC Pharma (EU) Limited, Ireland, in December 2019.

Key facts

Active substance
Tipifarnib
Disease / condition
Treatment of acute myeloid leukaemia
Date of first decision
10/03/2005
Outcome
Positive
EU designation number
EU/3/05/269

Sponsor's contact details

TMC Pharma (EU) Limited
The Black Church
St. Mary's Place
Dublin D07 P4AX
Ireland
Tel. +353 76 670 5745
E-mail: info@tmcpharma.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating